A-Z index
These pages make it easy to explore all of our resources by topic.
Note that we are currently updating this section of our website and will be adding more topics pages over the coming months.
- A
- B
- C
- D
- darknet/cryptomarkets
- deaths and overdose
- drug consumption rooms, an overview of provision and evidence
- drug-related deaths and mortality key indicator (under 'Our activities' ⇝>)
- drug overdose deathss in Europe, Frequelty asked questions (FAQ)
- emergency health consequences of cocaine use in Europe
- preventing overdose deaths in Europe ( 'Perspectives on drugs series')
- prevention of drug-related deaths
- take-home naloxone
- drug checking
- drug markets
- drug profiles — scientific descriptions of drugs including chemistry, pharmacology, synthesis, precursors and control status
- amphetamine drug profile
- barbiturates drug profile
- benzodiazepines drug profile
- BZP and other piperazines drug profile
- cannabis drug profile
- cocaine and crack drug profile
- fentanyl drug profile
- hallucinogenic mushrooms drug profile
- heroin drug profile
- khat drug profile
- LSD drug profile
- MDMA ('ecstasy') drug profile
- methamphetamine drug profile
- salvia divinorum drug profile
- synthetic cannabinoids and 'Spice' drug profile
- synthetic cathinones drug profile
- synthetic cocaine derivatives drug profile
- volatile substances drug profile
- driving and drugs
- Drug consumption facilities
- E
- ecstasy —see 'MDMA'
- EU4Monitoring Drugs (EU4MD)
- European Drug Report — annual overview of trends, data and analysis of the drug situation in Europe
- European Legal Database on Drugs (ELDD)
- European Union (EU)
- events (see meetings and events)
- F
- G
- H
- hallucinogenic mushrooms
- harm reduction — see 'health and social responses'
- health and social responses
- cocaine dependence, treatment for — reviewing current evidence
- drug consumption rooms, an overview of provision and evidence
- harm reduction
- Health and social responses guide
- hepatitis C treatment for injecting drug users
- Internet-based drug treatment
- legal framework of opioid substitution treatment (OST)
- methamphetamine users, health and social responses for
- monitoring drug treatment (under 'Our activities' ⇝)
- monitoring harm reduction (under 'Our activities' ⇝)
- monitoring health and social responses (under 'Our activities' ⇝)
- monitoring social reintegration (under 'Our activities' ⇝)
- opioid substitution treatment: strategies to prevent the diversion of
- preventing overdose deaths in Europe
- Prevention topics page
- hepatitis — see 'infectious diseases'
- heroin
- Homicide (drug-related)
- I
- J K L
- M
- MDMA
- meetings and events
- methamphetamine
- Mental health and drugs (comorbidity)
- Modelling
- N
- O
- opioids
- opioid substitution treatment (OST) — see 'health and social responses'
- overdoses — see 'deaths and overdose'
- Q P R
- Partners (under 'About' ⇝)
- European Parliament partner
- Council of the European Union partner
- European Commission partner
- European Police Office (Europol) partner
- European Centre for Disease Control (ECDC) partner
- European Medicines Agency (EMA) partner
- Eurojust partner
- European Police College (CEPOL) partner
- Reitox network partner
- United Nations Office on Drug and Crime (UNODC) partner
- Joint United Nations Programme on HIV/AIDS (UNAIDS) partner
- World Health Organisation (WHO) partner
- Pompidou Group partner
- Maritime Analysis and Operation Centre–Narcotics (MAOC-N) partner
- The International Criminal Police Organization (Interpol) partner
- World Customs Organisation (WCO) partner
- Inter-American Drug Abuse Control Commission (CICAD)
- European School Survey Project on Alcohol and Other Drugs (ESPAD) partner
- Candidate and potential candidate countries partners
- Neighbouring countries and Russia partners
- penalties, drug law penalties at a glance
- Perspectives on drugs series — topical analyses providing deeper insights into a selection of important issues
- benzodiazepine mis-use among high-risk opioid users in Europe
- cannabis: characteristics of frequent cannabis users
- cannabis: legal supply
- cannabis market in Europep
- cannabis resin market: changes in Europe
- cocaine: emergencies related to cocaine-use
- cocaine: trafficking to Europe
- comorbidity of drug use and mental health disorders
- drug consumption rooms, an overview of provision and evidence
- EU Drugs Strategy 2013–20
- hepatitis C treatment for injecting drug users
- heroin: trends in heroin use
- injection of synthetic cathinones
- internet-based drug treatment
- mass media campaigns — do they work?
- new psychoactive substances: health responses to
- new psychoactive substances: legal approaches to controlling
- opioid substitution treatment: strategies to prevent the diversion of
- opioid trafficking routes from Asia to Europe
- overdose deaths: preventing overdose deaths
- psychosocial interventions
- responses for methamphetamine users
- synthetic cannabinoids in Europe
- synthetic drug production in Europe
- treatment for cocaine dependence
- wastewater analysis and drugs — a European multi-city study
- policy
- precursors
- prevalence and patterns of drug use
- prevention
- prison
- production — see 'supply and production'
- public expenditure
- psychosocial interventions
- research, drug-related (under 'Our activities' ⇝)
- responses — see 'health and social responses'
- Partners (under 'About' ⇝)
- S
- salvia divinorum, drug profile
- scientific paper award (under 'Our activities' ⇝)
- social reintegration — monitoring (under 'Our activities' ⇝)
- statistics and data (under 'Data' ⇝)
- strategies and action plans
- supply, markets and production
- synthetic cannabinoids
- synthetic cathinones
- T
- U V W
- X Y Z
- young people